MedTrace Logo

Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia

NCT02745223 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-08-01

No results posted yet for this study

Summary

A study to establish safety, tolerability, and efficacy of PresbiDrops (CSF-1) in presbyopic subjects.

Conditions

Interventions

DRUG

PresbiDrops (CSF-1)

PresbiDrops (CSF-1) is a topical ophthalmic drug.

DRUG

Placebo

Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.

Sponsors & Collaborators

  • Orasis Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Eytan Blumental · Head of Ophthalmology Department, Rambam Medical Center, Haifa, Israel

  • Andreja Veselica · VID Medical Center, Nova Gorica, Slovenia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02745223 on ClinicalTrials.gov